Vivos Therapeutics, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Vivos Therapeutics, Inc. announced its 2025 Annual Meeting of Stockholders to be held virtually on November 4, 2025, seeking approval for director elections, an increased equity incentive plan, and auditor ratification.
NASDAQ
Vivos Therapeutics urges stockholders to vote in favor of proposals at the upcoming annual meeting after a year of regulatory approvals, revenue enhancement efforts, and balance sheet improvements.
NASDAQ
Vivos Therapeutics is asking stockholders to approve the 2024 Omnibus Equity Incentive Plan at the upcoming annual meeting on November 26, 2024.